Preclinical animal research serves as the foundation for understanding human disease and developing therapeutic interventions. However, a systemic vulnerability undermines this foundation: the widespread reliance on single-sex animal cohorts. Historically, researchers have favored single-sex designs—overwhelmingly defaulting to male subjects—to minimize experimental noise caused by hormonal cycles or simply out of historical inertia.
This methodological shortcut creates a profound blind spot. Sex is not a superficial variable; it is a fundamental regulatory layer that influences gene expression, metabolic rates, and cellular signaling pathways. When a biological mechanism or drug target is validated in only one sex, researchers risk mischaracterizing the disease entirely, leading to a failure of generalizability that stalls translation from bench to bedside.
The Molecular and Cellular Divergence
To understand why single-sex models fail to generalize, we must look at how sex chromosomes and hormones actively modulate cellular behavior. Biological pathways do not operate in a vacuum; they are constantly tuned by the endocrine environment.
Consider the protective role of estrogen in vascular health. In a study on atherosclerosis progression, Xiaoxuan Bai et al. mapped a complex signaling chain where cigarette tar induces endoplasmic reticulum stress, leading to necroptosis in vascular smooth muscle cells. However, because the authors based their findings solely on male mice, the model overlooks how estrogen's known vascular protective effects might alter or entirely halt this necroptotic pathway in females.
Similarly, sex hormones act as direct transcriptional regulators. As noted by Zhujing Ye in a study on radiation-induced brain injury, the gene Reprimo (RPRM) is explicitly repressed by estrogen. Deleting or targeting such a gene can yield completely different phenotypic outcomes depending on the sex of the subject, yet preclinical designs frequently leave these interactions unexamined.
[Preclinical Intervention]
│
├──► (In Male-Only Model) ──► Activates Pathway A ──► Therapeutic Success
│
└──► (In Female Organism) ──► Modulated by Estrogen/X-Chromosome ──► Pathway Altered/Blocked
When researchers isolate their observations to a single sex, they effectively lock a major biological dial to one setting, assuming the rest of the cellular machinery will function identically when that dial is turned.
Systemic Blind Spots Across Disease Domains
The generalizability crisis spans nearly every major domain of biomedical research, masking critical sex-specific differences behind single-sex data.
Neurology and Behavior
Brain disorders and behavioral phenotypes are heavily influenced by sexual dimorphism, yet neuroinflammation and cognitive decline models routinely default to single-sex cohorts. For instance, Haoran Wu et al. demonstrated that the compound catalpol alleviates depression-like behaviors by targeting the NLRP3 inflammasome, but did so exclusively in male mice.
Similarly, Ze Wang et al. linked Alzheimer's-related cooperative deficits to hypomyelination using only male subjects. Conversely, some neurodegenerative therapies are evaluated solely in female models, such as the ALS peptide interventions tested by Julia Post et al., which ignores well-documented gender-based variations in human ALS progression.
Pain and Inflammation
Pain processing is notoriously dimorphic, involving distinct immune cell populations in males and females. Despite this, multi-omics analyses of inflammation-induced hyperalgesia by Xiang Zhu et al. relied entirely on male rats, leaving the female molecular landscape of chronic pain unmapped.
Metabolism and Aging
Global transcriptomic shifts during aging or dietary interventions vary dramatically between sexes. Comprehensive tissue-specific aging profiles, such as those published by Emanuel Barth et al., and hepatic transcriptomic analyses of caloric restriction by Davina Derous et al., have provided foundational insights into longevity pathways—yet both configurations relied exclusively on male mice, omitting the distinct metabolic trajectories of aging females.
The Translational Mismatch
The danger of single-sex preclinical models becomes acute when they directly contradict human epidemiological realities. When a disease is clinically more prevalent or severe in one sex, studying it exclusively in the other creates a severe translational mismatch.
A striking example is found in gastroenterology. Irritable Bowel Syndrome (IBS) is significantly more prevalent in women, and its symptom severity fluctuates alongside hormonal cycles. Yet, the underlying neural mechanisms of visceral pain sensitization are frequently mapped using models like the one developed by Guang‐Bing Duan et al., which evaluated the EphB2-NMDA pathway in the basolateral amygdala using only male rats.
Similarly, inflammatory bowel diseases present distinct clinical severities between genders, but therapeutic pathways like STING inhibition are routinely validated in male-only configurations, as seen in the work by Lin-Kong Gong et al..
| Disease Context | Human Clinical Reality | Preclinical Model Design | Translational Risk |
|---|---|---|---|
| Irritable Bowel Syndrome | Higher prevalence and severity in females | Male-only rats (Guang‐Bing Duan et al.) | Mischaracterization of amygdala-driven pain pathways |
| Chemotherapy Cognitive Deficits | Affects both sexes; modulated by hormones | Male-only mice (Yue Hei et al.) | Overlooking blood-brain barrier protection mechanisms |
| Atherosclerosis | Dimorphic progression and onset | Male-only mice (Xiaoxuan Bai et al.) | Missing estrogenic mitigation of necroptosis |
When preclinical models ignore these clinical realities, the therapies derived from them are effectively optimized for a single sex, increasing the likelihood of failure or unforeseen toxicity during human clinical trials.
Mapping Dimorphism Directly
Overcoming this generalizability crisis requires a paradigm shift: treating sex not as a confounding variable to be eliminated, but as an essential biological axis to be mapped.
Some modern experimental designs demonstrate how this can be achieved. Instead of assuming uniformity, researchers can explicitly design dual-sex comparative frameworks. For example, Li Xu et al. utilized comparative transcriptomics to isolate female-biased olfactory genes, directly linking sexual dimorphism to specific behavioral outcomes. In the therapeutic space, Yonger Xue explicitly integrated gender-difference testing into a lipid nanoparticle stem-cell delivery model to confirm generalizability across contexts before moving forward.
By moving away from single-sex defaults and actively analyzing sex as a biological variable, preclinical research can ensure that discovered mechanisms are robust, reproducible, and ultimately safe and effective for the entire human population.